The Marseilles-based biopharmaceutical company, Innate Pharma SA, has moved its lead product for cancer, IPH 1101, into a Phase 1/2 trial in follicular lymphoma. The progress of the early-stage clinical trial was highighted in the company’s latest financial report to shareholders, which was issued on 29 August 2008.
